Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$21.55 - $29.29 $2,736 - $3,719
-127 Reduced 94.07%
8 $0
Q4 2023

Feb 09, 2024

SELL
$23.64 - $30.27 $452,800 - $579,791
-19,154 Reduced 99.3%
135 $3,000
Q3 2023

Oct 27, 2023

SELL
$26.74 - $40.81 $19,974 - $30,485
-747 Reduced 3.73%
19,289 $515,000
Q2 2023

Aug 11, 2023

BUY
$28.52 - $40.7 $44,633 - $63,695
1,565 Added 8.47%
20,036 $741,000
Q1 2023

May 05, 2023

BUY
$29.39 - $36.27 $276,354 - $341,046
9,403 Added 103.69%
18,471 $576,000
Q4 2022

Feb 10, 2023

SELL
$29.23 - $40.28 $194,262 - $267,700
-6,646 Reduced 42.29%
9,068 $270,000
Q3 2022

Nov 01, 2022

BUY
$37.92 - $63.74 $23,320 - $39,200
615 Added 4.07%
15,714 $599,000
Q2 2022

Aug 03, 2022

BUY
$47.98 - $62.75 $69,523 - $90,924
1,449 Added 10.62%
15,099 $823,000
Q1 2022

May 13, 2022

BUY
$49.85 - $96.11 $11,415 - $22,009
229 Added 1.71%
13,650 $852,000
Q4 2021

Feb 14, 2022

BUY
$77.3 - $105.0 $27,905 - $37,905
361 Added 2.76%
13,421 $1.35 Million
Q3 2021

Nov 12, 2021

BUY
$74.87 - $110.87 $973,085 - $1.44 Million
12,997 Added 20630.16%
13,060 $1.18 Million
Q2 2021

Aug 16, 2021

BUY
$66.8 - $100.45 $4,208 - $6,328
63 New
63 $6,000

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $609M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.